This application requests renewal of funding to serve as the Statistical and Data Management Center of the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT). IMPAACT is an international clinical trials network which is proposing to address objectives in NIAID high priority research areas for infants, children, adolescents, and pregnant and breastfeeding women living with HIV. Specifically: to evaluate novel and durable interventions targeting HIV infection; to identify strategies to reduce HIV reservoirs and control HIV replication in the absence of antiretroviral treatment (?ART-free remission?); to improve the diagnosis and treatment of tuberculosis, especially in those co-infected with HIV; and to improve the prevention and treatment of complications and co-infections of HIV. The application's specific aims and long-term objectives are: to support the international research agenda of IMPAACT by providing a group of highly-experienced statisticians, epidemiologists, data managers and other professionals who have a deep interest in research in HIV infection and its complications and co-infections; to support the development, conduct and analysis of IMPAACT studies with expert statistical and data management leadership and high quality clinical and laboratory data management and communications systems which comply with regulatory requirements, meet industry standards and are fully integrated into quality management system workflows; and to advance the mission of IMPAACT through innovation in study design and analysis and the development of efficient methods and systems, that facilitate the work of IMPAACT and promote harmonization and data sharing with collaborating organizations. The proposed SDMC consists of two components. One is a Statistical and Data Analysis Center at Harvard T.H. Chan School of Public Health which will provide biostatistical leadership. The second is a Data Management Center at Frontier Science & Technology Research Foundation which will provide expertise and leadership in data management systems and has primary responsibility for data collection, quality and integrity.

Public Health Relevance

The expertise provided by the Statistical and Data Management Center will help advance research concerning the treatment of infants, children, adolescents, pregnant and breastfeeding women living with HIV and co-infections such as tuberculosis. It will achieve this by ensuring that IMPAACT clinical trials and other studies are designed, conducted, and analyzed efficiently and to the highest standards using state-of-the-art, compliant clinical and laboratory information management systems that ensure complete and high-quality data. This research will continue to make significant contributions in advancing optimal treatment of infants, children, adolescents, pregnant and breastfeeding women living with HIV both in the United States and internationally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI068616-15
Application #
9988037
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Miller, Judith A
Project Start
2006-06-29
Project End
2027-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
15
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Harvard University
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Mulligan, Nikki; Best, Brookie M; Wang, Jiajia et al. (2018) Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS 32:729-737
Svensson, Elin M; du Bois, Jeannine; Kitshoff, Rene et al. (2018) Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. Br J Clin Pharmacol :
Nachman, Sharon; Alvero, Carmelita; Teppler, Hedy et al. (2018) Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. Lancet HIV 5:e715-e722
McFarland, Elizabeth J; Karron, Ruth A; Muresan, Petronella et al. (2018) Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children. J Infect Dis 217:1347-1355
Seddon, J A; Weld, E D; Schaaf, H S et al. (2018) Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done? Int J Tuberc Lung Dis 22:24-33
Pinto, Jorge A; Capparelli, Edmund V; Warshaw, Meredith et al. (2018) A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pediatr Infect Dis J 37:e29-e35
Momper, Jeremiah D; Best, Brookie M; Wang, Jiajia et al. (2018) Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS 32:2507-2516
Bender, Jeffrey M; Li, Fan; Adisetiyo, Helty et al. (2018) Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies. Microbiome 6:155
Koay, Wei Li A; Lindsey, Jane C; Uprety, Priyanka et al. (2018) Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1-Infected Infants. J Infect Dis 218:1085-1089
Angelidou, Konstantia; Palumbo, Paul; Lindsey, Jane et al. (2018) Defining Study Outcomes That Better Reflect Individual Response to Treatment. Pediatr Infect Dis J 37:258-262

Showing the most recent 10 out of 169 publications